| Nov 19 |
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
|
| Nov 14 |
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
|
| Nov 14 |
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
|
| Nov 8 |
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
|
| Nov 7 |
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
|
| Nov 6 |
Appili Therapeutics Announces Results of Special Meeting of Shareholders
|
| Nov 6 |
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
|
| Nov 6 |
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
|
| Oct 31 |
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
|
| Oct 31 |
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
|
